

Group Benefits Drug Prior Authorization Mounjaro (Tirzepatide)

The purpose of this form is to obtain the medical information required to assess your request for a drug on the Prior Authorization list under your drug plan benefit coverage. To avoid delays in processing your request, please ensure that all information, including contact information is complete. Completion of this form is not a guarantee of approval. If you have already purchased the drug, please attach all original receipts along with an **Extended Health Care Claim** form. All costs incurred to complete this form are the plan member's responsibility. If you are registered for the Plan Member Secure Site and have provided an email address, you will receive an email notification when the prior authorization decision is available on your claims statement. If you are not registered on the Plan Member Secure Site, you will be notified of the prior authorization decision by mail.

Important: Please ensure the most current unaltered version of the form is completed and signed. To download the most recent version of the Drug Prior Authorization form go to www.manulife.ca

| 1 | Plan member and patient information | Plan contract number | Plan member certificate | number | Plan sponsor | | | | | |
|---|--|---|---------------------------------|--------------------------------|--------------|-----------------------------|-------------|------------|--|--|
| | | Plan member name (first, middle initial, last) Date of birth (dd/mmm/yy | | | | | | /mmm/yyyy) | | |
| | To be completed by plan member | | | | | | | | | |
| | | Plan member address (number | er, street and apt.) | City or to | own Province | ! | Postal code | | | |
| | Patient name (first, middle initial, last) | | Patient | nt date of birth (dd/mmm/yyyy) | | Relationship to plan member | | | | |
| | | Patient's preferred daytime ph | none number Patient's email | address (option | al) | | | | | |
| | | Irug coverage under any o | other group p | olan? | | ○ Yes ○ N | | | | |
| | | Name of insurance company | e of insurance company | | | | | | | |
| | Plan contract number Plan member | | member certificate number | ate number | | | | | | |
| | | Is this drug covered und | der the other group plan? | | | | ○ Yes | ○ No | | |
| | | If <i>no</i> , why was the drug declined by the other group plan? Please attach the other group plan decline notice (typically a letter or statement). We need this decline notice to see if this drug can be approved. If this is a renewal a current decline notice is required. | | | | | | | | |
| | | Did your plan sponsor recently transfer your drug benefits to Manulife? | | | | | ○ Yes | ○ No | | |
| | | Before joining Manulife, were you receiving coverage for this drug through your previ insurance company? | | | | ous | ○ Yes | ○ No | | |
| | | If yes, Attach proof of payment (a copy of a pharmacy receipt showing payment from prior Explanation of Benefits from the prior insurance company). Proceed to section 7. | | | | | | | | |
| | | | | | | | ance comp | any or an | | |
| | | If no applies to any of the | any of the above two questions, | | | | | | | |
| | | Proceed to section 2 | | | | | | | | |

| 2 | Provincial Plans To be completed by prescribing physician | Most provinces offer some form of drug coverage to their residents. Your Manulife drug plan supplements the coverage provided by provincial plans. It is important that you or your doctor (if required) apply to the applicable provincial program to ensure there are no delays in your drug reimbursement. Check with your doctor or login to the Manulife Provincial Drug Plans Resource Centre on our Plan Member Secure Site at www.manulife.ca/planmember to confirm if the drug you have been prescribed may be eligible for coverage under a provincial plan. If the drug you have been prescribed is listed under a provincial program, you will need to apply to the program before consideration can be given under your Manulife drug plan. | | | | | | | |
|---|--|---|------------------------------|----------------|--------------|--------|--|--|--|
| | | Has application been made to the provincial prog | | ar rianame are | Yes | ○ No | | | |
| | | If no, why? | unitor coverage. | | | | | | |
| | | Has the patient been approved for coverage by th | e provincial program for thi | s drug? | ○ Yes | ○ No | | | |
| | | ir no, advise why the request was declined | | | | | | | |
| | | In Ontario, for patients that qualify for cover drug is an EAP drug, a copy of the approval o Manulife can complete the assessment of th | r denial from EAP must b | | | | | | |
| 3 | Patient Assistance Programs | Have you enrolled in the Patient Assistance Progr | am? | | O Yes | ○ No | | | |
| | To be completed by plan member | If yes, please provide your Patient Assistance Program ID Number: Case Manager name and contact details | | | | | | | |
| | | | | | | | | | |
| 4 | Medical information | Drug strength and dosage | | | | | | | |
| | To be completed by prescribing physician | Where will the treatment be administered? Home MD Office Private Clinic Hospital/In-patient Hospital/Out-patient Is the MD office located in a hospital? Will the drug be administered in the MD office or in another area of the hospital? (describe below) | | | | | | | |
| | | | | | | | | | |
| | | If the treatment is not being administered at home, please provide: | | | | | | | |
| | | Name of private clinic/hospital | | Tel | ephone numbe | er | | | |
| | | Address (number, street and apt.) | City or town | Province | Postal code | | | | |
| | | | | | | | | | |

4 Medical information (continued)

To be completed by prescribing physician

| Please select the diagnosis for which the drug has been prescribed and respond to the corresponding |
|---|
| auestions. |

| Type 2 Diabetes Mellitus | | | | | | | | |
|---|-------|------|--|--|--|--|--|--|
| ○ Initial Criteria | | | | | | | | |
| Does patient have a confirmed diagnosis of type 2 diabetes mellitus? | ○ Yes | ○ No | | | | | | |
| Has patient achieved adequate glycemic control with the maximum tolerated dose of metformin and diet and exercise? | ○ Yes | ○ No | | | | | | |
| Will Mounjaro be used as an adjunct to diet and exercise? | ○ Yes | ○ No | | | | | | |
| Please list all drugs that will be taken in combination with Mounjaro: | | | | | | | | |
| | | | | | | | | |
| Does patient have documented intolerance or contraindication to metformin? | ○ Yes | ○ No | | | | | | |
| Will dose of Mounjaro exceed 15 mg once weekly? | ○ Yes | ○ No | | | | | | |
| Will Mounjaro be given in combination with other GLP-1 analogs? | ○ Yes | ○ No | | | | | | |
| Note: Initial approval is limited to 12 months. Additional information is required after 12 months in order to assess for further coverage. | | | | | | | | |
| Renewal Criteria | | | | | | | | |
| Is there documented objective evidence of continued benefit for the patient (i.e., patient has a decrease in HbA1c)? | ○ Yes | ○ No | | | | | | |
| Will Mounjaro be used as an adjunct to diet and exercise? | ○ Yes | ○ No | | | | | | |
| Will Mounjaro be given in combination with other GLP-1 analogs? | ○ Yes | ○ No | | | | | | |
| Will dose of Mounjaro exceed 15 mg once weekly? | ○ Yes | ○ No | | | | | | |
| Any other diagnosis | | | | | | | | |
| Please provide the specific diagnosis and any Canadian clinical research that supports the use of this drug in your patient's context. | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

| 5 | Drug history | Risk of drug interaction Patient has contraindication Other Please provide medical rationale | | | | | | | |
|---|--|--|--|--------------|-----------------------|-------------|--|---|------------------------------------|
| | To be completed by prescribing physician | | | | | | | | |
| | | For the selected diagnosis | s, please provide all previou | ıs and cur | rent drug t | herapies ir | n the ar | rea below. | |
| | | Drug name | | | Start date (| yyyy/mmm) | Er | nd date (yyyy/m | nmm) |
| | | Please specify the outcom | ne: | gy/Adverse | e Event) | Inadeq | uate/S | Suboptimal F | Response |
| | | Will the patient be continuing on this medication in addition to new therapy? Yes No | | | | | | | |
| | | Drug name | | | Start date (yyyy/mmm) | | | End date (yyyy/mmm) | |
| | | Please specify the outcom | Please specify the outcome: | | | | | | |
| | | Will the patient be continuing on this medication in addition to new therapy? Yes Yes | | | | | | ○ No | |
| | | Drug name | | | Start date (| yyyy/mmm) | Er | nd date (yyyy/m | nmm) |
| | | Please specify the outcome: Intolerance (Allergy/Adverse Event) Inadequate/Suboptimal Response Will the patient be continuing on this medication in addition to new therapy? Yes No | | | | | | | |
| 6 | Physician information | Prescribing physician's name | | | | Specialty | | | |
| | To be completed by prescribing physician | Address (number, street and suite | <u>e</u>) | City or town | 1 | Provin | ce | Postal code | |
| | | Telephone number | Extension | Fax nur | mber | | | - | |
| | Physician authorization | I certify that the information in this form is true and complete to the best of my knowledge. The information in this statement will be kept in a Group Benefits health file with Manulife and might be accessible by the patient or third parties to whom access has been granted or those authorized by law. By providing the information, I consent to such unedited release of any information contained herein. | | | | | | | |
| | | Physician's signature | | | | | Da | ate signed (dd/ | mmm/yyyy) |
| 7 | Authorization and Plan member signature | | e and/or my dependents of lent drug that Manulife pro | | major age (| ("Depende | nts") re | equire the dr | ug named |
| | To be signed by plan member Manulife and/or its service providers, its reinsurers, and their service providers disclose my personal information related to this application ("Personal Information or The assessment of the drug authorization request. Managing my Group Benefits plan. Assessing and processing claims. Auditing and investigation of claims. Patient assistance programs, if applicable. And/or other purposes identified in the Personal Information Statement for plans (collectively, the "Purposes"). Any person or organization who has Personal Information about me that is requited this drug authorization request, including any medical and health care profession or any other medical or health care related facility, professional regulatory bodical administrator, insurer, investigative agency, and any other administrators of other use, maintain, disclose and exchange this information with each other and with its service providers, for the Purposes. | | | | | | mploye for Ma s, instit any emenits | e purposes ers' Group B nulife to ass tution, pharr ployer, grou programs to | enefits ess nacy p plan o collect, |

7 Authorization and Plan member signature (continued)

To be signed by plan member

I understand:

- A Manulife approved pharmacy vendor may engage me in the capacity of case management to provide support as part of this program. I acknowledge that participation in this program is entirely voluntary.
 My decision to participate will not have any impact on the assessment of my claim.
- If my Manulife plan recommends purchasing a drug that requires prior authorization from a preferred pharmacy or provider, a case manager may contact me, my doctor and/or patient assistance program to arrange to have my prescription(s) transferred to the preferred pharmacy or provider.
- That except where there are contractual restrictions, Manulife employees, authorized organizations, service providers and reinsurers are located both within Canada and outside of Canada. Therefore, my Personal Information may be subject to interprovincial or cross-border transfers for the Purposes and may be subject to the laws of those jurisdictions.
- I may withdraw my consent for certain uses of my Personal Information, subject to legal and contractual
 restrictions. If I do so, Manulife may treat my withdrawal of consent as a request to dismiss, rescind or
 terminate my claim.

l agree:

- A photocopy or electronic version of this consent is valid.
- I have the right to access and verify my Personal Information maintained in Manulife's files and to request any factually inaccurate Personal Information be corrected, if appropriate.
- Requests can be sent to: Privacy Officer Manulife, P.O. Box 1602, Del Stn 500-4-A, Waterloo, Ontario N2J 4C6 or Canada_Privacy@manulife.ca.
- For more information, I can review the <u>Personal Information Statement for Employers' Group Benefits Plans</u> and the <u>Canadian Privacy Policy</u>.

I confirm that:

- The information I have given in this request is true and accurate.
- By signing, I give permission to and/or confirm that I have obtained the individual's consent for the
 collection, use, disclosure or otherwise processing of the individual's Personal Information for the
 Purposes (as these terms are defined above).

Plan member's signature

Date signed (dd/mmm/yyyy)

Protecting your personal information is important to us. People who can see your personal information are:

- Manulife employees who need to see your information to do their jobs.
- People you've given permission to.

To find out more about Manulife's privacy policy please see manulife.ca

8 Mailing instruction

Use the Submit a Claim Feature on the Plan Member Secure Site **OR** mail or fax your completed form to the appropriate address:

If you live in Quebec:

Manulife Group Benefits Health Claims Attention Prior Authorization Team PO BOX 2580, STATION B MONTREAL QC H3B 5C6

Fax: 1-855-752-0404

Please retain a photocopy for your files.

If you live outside Quebec:

Manulife Group Benefits Health Claims Attention Prior Authorization Team PO BOX 1653 WATERLOO ON N2J 4W1

Fax: 1-855-752-0404